Literature DB >> 9547352

Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene.

H Li1, S A Oehrlein, T Wallerath, I Ihrig-Biedert, P Wohlfart, T Ulshöfer, T Jessen, T Herget, U Förstermann, H Kleinert.   

Abstract

In primary human umbilical vein endothelial cells (HUVECs), incubation with phorbol-12-myristate-13-acetate (PMA) enhanced basal and bradykinin-stimulated nitric oxide production. In the HUVEC-derived cell line EA.hy 926, PMA and phorbol-12,13-dibutyrate stimulated endothelial nitric oxide synthase (NOS III) mRNA expression in a concentration- and time-dependent manner. Maximal mRNA expression (3.3-fold increase) was observed after 18 hr. NOS III protein and activity were increased to a similar extent. The specific protein kinase C (PKC) inhibitors bisindolylmaleimide I (1 microM), Gö 6976 [12-(2 cyanoethyl)-6,7,12, 13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo-[3, 4-c]carbazole] (1 microM), Ro-31-8220 [3-[1-[3(amidinothio)propyl-1H-inoyl-3-yl]3-(1-methyl-1H- indoyl-3-yl) maleimide methane sulfonate] (1 microM), and chelerythrine (3 microM) did not change NOS III expression when applied alone, but they all prevented the up-regulation of NOS III mRNA produced by PMA. Of the PKC isoforms expressed in EA.hy 926 cells (alpha, beta I, delta, epsilon, eta, zeta, lambda, and mu), only PKC alpha and PKC epsilon showed changes in protein expression after PMA treatment. Incubation of EA.hy 926 cells with PMA for 2-6 hr resulted in a translocation of PKC alpha and PKC epsilon from the cytosol to the cell membrane, indicating activation of these isoforms. After 24 hr of PMA incubation, both isoforms were down-regulated. The time course of activation and down-regulation of these two PKC isoforms correlated well with the PMA-stimulated increase in NOS III expression. When human endothelial cells (ECV 304 or EA.hy 926) were transiently or stably transfected with a 3.5-kb fragment of the human NOS III promoter driving a luciferase reporter gene, PMA stimulated promoter activity up to 2.5-fold. On the other hand, PMA did not change the stability of the NOS III mRNA. These data indicate that stimulation of PKC alpha, PKC epsilon, or both by active phorbol esters represents an efficacious pathway activating the human NOS III promoter in human endothelium.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547352     DOI: 10.1124/mol.53.4.630

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Modulation of ecto-5'-nucleotidase by phospholipids in human umbilical vein endothelial cells (HUVEC).

Authors:  Annette Pexa; Andreas Deussen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

2.  The effects of modulating eNOS activity and coupling in ischemia/reperfusion (I/R).

Authors:  Kerry-Anne A Perkins; Sailesh Pershad; Qian Chen; Sloane McGraw; Jovan S Adams; Christopher Zambrano; Samuel Krass; Jeffrey Emrich; Brandon Bell; Michael Iyamu; Catherine Prince; Helen Kay; Jane Chun-wen Teng; Lindon H Young
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

3.  The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide-synthase system in vitro.

Authors:  Thomas R Räthel; Jürgen F Leikert; Angelika M Vollmar; Verena M Dirsch
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  The transport activity of the human cationic amino acid transporter hCAT-1 is downregulated by activation of protein kinase C.

Authors:  P Gräf; U Förstermann; E I Closs
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

5.  Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension.

Authors:  T Wallerath; K Witte; S C Schäfer; P M Schwarz; W Prellwitz; P Wohlfart; H Kleinert; H A Lehr; B Lemmer; U Förstermann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 6.  Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.

Authors:  Ulrich Förstermann; Huige Li
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization.

Authors:  Michael Potente; Carmen Urbich; Ken-ichiro Sasaki; Wolf K Hofmann; Christopher Heeschen; Alexandra Aicher; Ramya Kollipara; Ronald A DePinho; Andreas M Zeiher; Stefanie Dimmeler
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

8.  Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes.

Authors:  Cathy Grutzmacher; SunYoung Park; Yun Zhao; Margaret E Morrison; Nader Sheibani; Christine M Sorenson
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-17

9.  YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells.

Authors:  Ming-Shyan Chang; Wen-Sen Lee; Che-Ming Teng; Horng-Mo Lee; Joen-Rong Sheu; George Hsiao; Chien-Huang Lin
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

10.  Mechanisms related to the cardioprotective effects of protein kinase C epsilon (PKC epsilon) peptide activator or inhibitor in rat ischemia/reperfusion injury.

Authors:  Jane Chun-wen Teng; Helen Kay; Qian Chen; Jovan S Adams; Christopher Grilli; Giuseppe Guglielmello; Christopher Zambrano; Samuel Krass; Adrian Bell; Lindon H Young
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.